Abstract
Aim:
To study the degrees of influence of changing side ester chains at position C20 of camptothecin on the anti-tumor activity of the molecules.
Methods:
The esterification reaction of camptothecin 1 and 9-nitrocamptothecin 2 with crotonic anhydride in pyridine gave the corresponding esters 3 and 4, respectively. The acylation of 1 and 2 with cinnamoyl chloride gave products 7 and 8. Epoxidation reaction of 3 and 4 with m-chloroperoxybenzoic acid in benzene solvent gave the products 5 and 6. Esters 3, 4, and 5 were tested for anti-tumor activity against 14 human cancer cell lines.
Results:
Both in vitro and in vivo anti-tumor activity studies for these esters were conducted and the data demonstrated positive results, that is, these esters were active against the tested tumor lines.
Conclusion:
Alkenyl esters 3 and 4 showed strong anti-tumor activity in vitro against 14 different cancer cell lines. Ester 3 was active against human breast carcinoma in mice and the toxicity of the agent was not observed in mice during the treatment, implying that this agent is effective for treatment with low toxicity.
Similar content being viewed by others
Article PDF
References
Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA . Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata. J Am Chem Soc 1966; 88: 3888–90.
Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB . Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep Part 1 1970; 54: 461–70.
Gottlieb JA, Luce JK . Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 1972; 56: 103–5.
Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS . Phase I clinica l trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 1972; 56: 515–21.
Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG . Phase II studies of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972; 56: 95–101.
Schaeppi U, Fleishman RW, Cooney DA . Toxicity of camptothecin (NSC-100880). Cancer Chemother Rep 1974; 5: 25–36.
Wani MC, Ronman PE, Lindley LT, Wall ME . Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogs. J Med Chem 1980; 23: 554–60.
Cao Z, Harris N, Kozielski A, Vardeman D, Stehlin J, Giovanella B . Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity. J Med Chem 1998; 41: 31–7.
Zhao H, Lee C, Sai P, Choe Y, Boro M, Pendri A, et al. 20-O-Acylcamptothecin derivatives: evidence for lactone stablization. J Org Chem 2000; 65: 4601–6.
Cao Z, Mendoza J, Early J, Harris N, Kozieski A, Liehr J, et al. Structure-activity relationship of alkyl camptothecin esters. T he Camptothecins: unfolding their anticancer potential. Ann NY Acad Sci 2000; 922: 122–35.
Cao Z, Mendoza J, Early J, Harris N, Kozieski A, Liehr J, et al. Structure-activity relationship of alkyl 9-nitrocamptothecin esters. Acta Pharmacol Sin 2003; 24: 109–19.
Cao Z, Armstrong K, Shaw M, Petry E, Harris N . Nitration of camptothecin with various inorganic nitrate salts in concentrated surfuric acid: a new preparation of anticancer drug 9-nitrocampto-thecin. Synthesis 1998; 1724–30.
Cao Z . Preparation of 14-nitrocamptothecin derivatives by reactions of camptothecin with nitronium tetrofluoroborate in acidic solvents. J Chem Soc Perkin Trans 1 1996; 2629–32.
Cao Z . An alternative preparation of camptothecin 20(S)-acetate. Synth Commun 1997; 27: 2013–9.
Author information
Authors and Affiliations
Corresponding author
Additional information
Financial support from the Stehlin Foundation for Cancer Research.
Rights and permissions
About this article
Cite this article
Cao, Zs., Mendoza, J., Dejesus, A. et al. Synthesis and anti-tumor activity of alkenyl camptothecin esters. Acta Pharmacol Sin 26, 235–241 (2005). https://doi.org/10.1111/j.1745-7254.2005.00031.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00031.x